文献速递系统性红斑狼疮

LOOPS注册研究:SLE活动性肾脏受累的三种诱导治疗策略的临床与免疫学结局

Clinical and immunological outcomes of rituximab-based, mycophenolate mofetil-based and cyclophosphamide-based treatment strategies for systemic lupus erythematosus with active kidney involvement from LOOPS registry.
PubMed 文献 · RMD Open · 2026-09-25

该回顾性注册研究比较了利妥昔单抗、吗替麦考酚酯或静脉环磷酰胺联合糖皮质激素诱导治疗SLE活动性狼疮肾炎患者的52周结局,发现三组在完全肾脏缓解率、蛋白尿改善、肾功能、疾病活动度、复发率及安全性方面均无显著差异,但各策略内部呈现不同的免疫表型变化模式。

要点

  • 三种诱导策略在52周完全肾脏缓解率及蛋白尿改善方面无显著差异
  • 各策略内部免疫表型变化模式不同,但策略间纵向变化差异未获证实
  • 全面免疫表型分析可能有助于未来狼疮肾炎的应答分层与精准医学

核心结论

  • RTX为基础、MMF为基础和IVCY为基础的策略对活动性狼疮肾炎的52周临床有效性无显著差异。

研究设计与样本

  • 回顾性分析LOOPS注册中接受RTX、MMF或IVCY单药诱导治疗(均联合糖皮质激素)的SLE活动性狼疮肾炎患者。
  • 共同主要终点为第52周完全肾脏缓解(CRR)率和尿蛋白肌酐比<0.7 g/gCr的达标率。
  • 采用多色流式细胞术评估治疗前后外周血免疫细胞亚群。

主要发现

  • 第52周时各组间CRR率及蛋白尿改善无显著差异。
  • 估计肾小球滤过率变化、疾病活动度指标及合并糖皮质激素剂量组间亦无显著差异。
  • 策略内探索性分析显示RTX组B细胞亚群比例降低,MMF和IVCY组呈更广泛降低(包括活化T细胞)。
  • 治疗策略与时间的交互作用不显著,无证据表明策略间纵向变化存在差异。

关键数值与推荐

  • 共同主要终点之一为尿蛋白肌酐比<0.7 g/gCr。
  • 共同主要终点之一为完全肾脏缓解(CRR)率。
  • 主要评估时间点为第52周。

临床怎么用

  • 三种诱导策略均可作为SLE活动性狼疮肾炎的候选方案,52周疗效无显著差异。
  • 免疫表型动态监测可能辅助未来应答分层与精准治疗决策。

局限性

  • 为回顾性注册研究设计。
  • 策略间免疫表型纵向变化差异未获统计学证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the clinical outcomes and explore longitudinal peripheral blood immunophenotypic changes associated with rituximab (RTX)-based, mycophenolate mofetil (MMF)-based or intravenous cyclophosphamide (IVCY)-based treatment strategies for patients with systemic lupus erythematosus (SLE) and active lupus nephritis. METHODS: We retrospectively analysed patients with SLE and active lupus nephritis enrolled in the LOOPS registry who received single-agent induction therapy with RTX, MMF or IVCY in addition to glucocorticoids (GCs). The co-primary endpoints were the achievement rates of complete renal response (CRR) and urinary protein-to-creatinine ratio <0.7 g/gCr at week 52. Secondary endpoints included renal function, proteinuria, disease activity, relapse rate and safety. Peripheral blood immune cell subsets were assessed by multicolour flow cytometry before and after treatment. RESULTS: At week 52, no significant differences were observed in CRR rates or improvement in proteinuria among the groups. Changes in estimated glomerular filtration rate, disease activity measures and concomitant GC dose also did not differ significantly. Exploratory within-strategy analyses showed reduced B-cell subset proportions with RTX and broader reductions, including in activated T cells, with MMF and IVCY. However, treatment strategy-by-time interaction was not significant, providing no evidence of between-strategy differences in longitudinal changes. CONCLUSION: The 52-week clinical effectiveness of the RTX-based, MMF-based and IVCY-based strategies for active lupus nephritis did not differ significantly. Different within-strategy immunophenotypic patterns were observed, but between-strategy differences were not confirmed. Comprehensive immunophenotyping may help characterise immune dynamics and support future response stratification and precision medicine for lupus nephritis.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Ueno M, Miyagawa I, Tanaka H, et al. Clinical and immunological outcomes of rituximab-based, mycophenolate mofetil-based and cyclophosphamide-based treatment strategies for systemic lupus erythematosus with active kidney involvement from LOOPS registry. RMD Open. 2026. PMID: 42791028. doi:10.1136/rmdopen-2026-007370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。